Charité-Universitätsmedizin Berlin, Department of Nephrology and Medical Intensive Care, Berlin, Germany.
Berlin Institute of Health (BIH), Berlin, Germany.
Genet Med. 2021 Jul;23(7):1219-1224. doi: 10.1038/s41436-021-01127-8. Epub 2021 Mar 12.
Chronic kidney disease (CKD) is a major health-care burden. Increasing evidence suggests that a considerable proportion of patients are affected by a monogenic kidney disorder.
In this study, the kidney transplantation waiting list at the Charité was screened for patients with undetermined cause of CKD. By next-generation sequencing (NGS) we targeted all 600 genes described and associated with kidney disease or allied disorders.
In total, 635 patients were investigated. Of these, 245 individuals had a known cause of CKD (38.5%) of which 119 had a proven genetic disease (e.g., ADPKD, Alport). The other 340 patients (53.5%) were classified as undetermined diagnosis, of whom 87 had kidney failure (KF) onset <40 years. To this latter group genetic testing was offered as well as to those patients (n = 29) with focal segmental glomerulosclerosis (FSGS) and all individuals (n = 21) suspicious for thrombotic microangiopathy (TMA) in kidney biopsy. We detected diagnostic variants in 26 of 126 patients (20.6%) of which 14 of 126 (11.1%) were pathogenic or likely pathogenic. In another 12 of 126 (9.5%) patients, variants of unknown significance (VUS) were detected.
Our study demonstrates the diagnostic value of comprehensive genetic testing among patients with undetermined CKD.
慢性肾脏病(CKD)是一个主要的医疗保健负担。越来越多的证据表明,相当一部分患者受到单基因肾脏疾病的影响。
在这项研究中,夏洛蒂医院的肾移植等候名单筛选出了原因不明的 CKD 患者。通过下一代测序(NGS),我们针对所有 600 个与肾脏疾病或相关疾病相关的描述性基因进行靶向检测。
总共调查了 635 名患者。其中,245 名患者有已知的 CKD 病因(38.5%),其中 119 名患有已证实的遗传疾病(如 ADPKD、Alport)。另外 340 名患者(53.5%)被归类为未确定诊断,其中 87 名患者的肾衰竭(KF)发病年龄<40 岁。对后者组提供了基因检测,对 29 名局灶节段性肾小球硬化症(FSGS)患者和所有 21 名疑似肾活检中血栓性微血管病(TMA)的患者也提供了基因检测。我们在 126 名患者中的 26 名(20.6%)患者中检测到了诊断性变异,其中 14 名(11.1%)为致病性或可能致病性变异。在另外的 12 名(9.5%)患者中,检测到了意义不明的变异(VUS)。
我们的研究表明,在原因不明的 CKD 患者中进行全面基因检测具有诊断价值。